Blog · Evidence, in plain language

Your patient has seen the headlines about a new ADHD medicine.

A patient with ADHD may arrive asking about Simtriyo, a medicine in a new class that was approved this summer and given its controlled substance schedule this fall. The question sounds simple and is not: a new mechanism invites hope that the evidence has not yet earned or ruled out. This post sets out what the regulators actually decided, what the approval trials measured, and which parts of the conversation sit in your room and which sit with the prescriber.

By Karel Winner, DNP, PMHNP-BC · Published November 10, 2026

This post is professional education, not clinical guidance for an individual patient. It summarizes two regulator decisions and the FDA label. Prescribing decisions belong to the patient and the prescriber.

What the regulators decided

On July 24, 2026, the Food and Drug Administration approved centanafadine, brand name Simtriyo, for attention-deficit/hyperactivity disorder in adults and in patients aged 6 years and older weighing at least 20 kg. The label describes it as a norepinephrine-dopamine-serotonin reuptake inhibitor, a class that adds serotonin to the two messengers the established stimulants act on, and it classifies the medicine plainly as a central nervous system stimulant. On October 30, 2026, the Drug Enforcement Administration placed centanafadine in Schedule III of the Controlled Substances Act, in an interim final rule effective that day, with public comments open until November 30, 2026. Approval rested on four randomized, double-blind, placebo-controlled trials of six weeks each, randomizing 1,845 people in total: 480 children aged 6 to 12 and 459 adolescents aged 13 to 17 rated on the ADHD Rating Scale-5, and 906 adults aged 18 to 55 rated on the Adult ADHD Investigator Symptom Rating Scale, in studies that used a different formulation of the same medicine. Symptoms improved more on the medicine than on placebo in every study, by 2.7 to 5.6 points beyond placebo on the scales used.

Two limits in that record matter for any session conversation. No trial compared centanafadine with another ADHD medicine, so nothing in the evidence ranks it against methylphenidate, amphetamine products, or the non-stimulants a patient may already take. And six weeks is the whole of the direct evidence, which leaves long-term benefit and long-term safety unmeasured. The label carries a boxed warning on suicidal thoughts and behaviors in pediatric patients, based on higher rates in treated children aged 6 to 12 in one six-week study, and on abuse, misuse, and addiction. In adults, the most common adverse reactions were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea.

What belongs in the therapy room

The hope itself is session material. A patient who lights up at a new approval is often telling you what their current treatment is not doing: the afternoon crash, the appetite loss, the feeling of being managed rather than helped. Naming that precisely, as a list of specific problems rather than a general wish for something better, turns a headline into information a prescriber can act on. The reverse case deserves the same care. A patient whose treatment works and who still wants the new option is usually chasing the idea that a newer mechanism must mean a better fit, and the trial record gives that idea no support: the measured advantage was over placebo, modest in size, and placebo groups improved substantially too, helped by structure and regular review. That observation can be offered honestly in session, because it points back to the work your room already does on routines, task initiation, and recovery from lapses.

Observation is also yours, whichever way the prescribing decision goes. If a patient starts this medicine, the label's own list defines what is worth tracking in plain terms: sleep, appetite, headaches, nausea, mood shifts, any emergence of manic or psychotic symptoms, tics, and changes in blood pressure or heart rate reported at medical visits. Reports that stay concrete and dated, what changed, when it started, and how it affects work or school, are the reports that let a prescriber judge whether a six-week trial of this medicine is succeeding. A safety signal is different from a side effect report: new or worsening suicidal thoughts in a younger patient, or signs of misuse, call for prompt contact with the prescriber and the crisis standard below, not for waiting until the next scheduled session topic.

What belongs to the prescriber

Eligibility, screening, and switching are prescribing judgments. The label instructs prescribers to assess abuse and addiction risk, cardiac disease, blood pressure and heart rate, risk factors for a manic episode, and any history of tics or Tourette's syndrome before starting, and it warns against use in serious cardiac disease. One interaction deserves a therapist's awareness because it is common in this population: the label warns that combining the medicine with other serotonergic drugs may cause serotonin syndrome, and many adults with ADHD also take an antidepressant, so the full medication list is a prescriber question, never a session adjustment. Schedule III status is also the prescriber's territory: it brings the registration, recordkeeping, and prescription rules of that schedule with it, and it reflects the DEA's judgment that the medicine has an accepted medical use with an abuse potential below the Schedule I and II substances. Whether a switch is worth attempting at all, given that no head-to-head evidence exists, is a decision that rests on the patient's current response and tolerability, and it is not settled by enthusiasm in either room.

Sources

U.S. Food and Drug Administration prescribing information for Simtriyo (centanafadine), NDA 218145, revised October 2026: the approved indication, the boxed warnings, the warnings and precautions, the most common adverse reactions, and the four clinical studies in section 14. FDA prescribing information.

U.S. Food and Drug Administration approval letter for NDA 218145, July 24, 2026: the application is approved for the treatment of attention-deficit/hyperactivity disorder, and marketing was tied to completion of controlled substance scheduling. FDA approval letter.

Drug Enforcement Administration, Schedules of Controlled Substances: Placement of Centanafadine in Schedule III, interim final rule, Federal Register volume 91, page 68470, October 30, 2026, Docket No. DEA-1743: the rule is effective October 30, 2026, and comments are due November 30, 2026. DEA interim final rule in the Federal Register.

If a patient is having thoughts of harming themselves, the crisis standard applies: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service.